文献速递胸部肿瘤支持与姑息治疗

检查点抑制剂诱发的类结节病反应

Sarcoidosis-Like Reactions Induced by Checkpoint Inhibitors.
PubMed 文献 · J Thorac Oncol · 2018-05-12

本文综述免疫检查点抑制剂(ICI)诱发的类结节病反应的文献数据,涉及抗CTLA-4抗体、PD-1抑制剂和PD-L1抑制剂三类。反应在组织学、器官受累模式和临床表现上与结节病难以区分,最常见于胸腔内(肺和/或纵隔淋巴结)和皮肤。从ICI启动至类结节病反应发生的中位时间平均为14周,无论是否干预,反应在ICI治疗后均改善或消退。

要点

  • ICI诱发的类结节病反应与结节病在组织学、器官受累和临床表现上难以区分。
  • 最常见部位为胸腔内(肺和/或纵隔淋巴结)和皮肤。
  • 从ICI启动至反应发生的中位时间平均为14周。

核心结论

  • ICI诱发的类结节病反应与结节病难以区分,但通常在ICI治疗后改善或消退。
  • 该反应的出现可能提示ICI抗肿瘤有效,应继续ICI治疗。
  • 类结节病反应不强制抗结节病治疗,尤其无症状时。

研究设计与样本

  • 本文为综述,汇总医学文献中关于ICI诱发类结节病反应的数据。
  • 涉及抗CTLA-4抗体、PD-1抑制剂和PD-L1抑制剂三类ICI。

主要发现

  • 类结节病反应与结节病在组织学、器官受累模式和临床表现上相似。
  • 最常见部位为胸腔内(肺和/或纵隔淋巴结)和皮肤。
  • 从ICI启动至类结节病反应发生的中位时间平均为14周。
  • 无论是否干预,反应在ICI治疗后均改善或消退。
  • 有证据提示类结节病反应的出现提示ICI抗肿瘤有效。

关键数值与推荐

  • 从ICI启动至类结节病反应发生的中位时间平均为14周。
  • 无症状类结节病反应不强制抗结节病治疗。
  • 需治疗时可继续ICI并加用抗结节病治疗,标准抗结节病方案似乎有效。

临床怎么用

  • 识别ICI治疗中出现类结节病反应,尤其胸腔内和皮肤部位。
  • 无症状者可不干预,需治疗时继续ICI并加用抗结节病治疗。
  • 类结节病反应出现时考虑ICI抗肿瘤有效,不宜轻易停用。

局限性

  • 本文为综述,未报告原始研究的具体样本量、阈值或统计值。
  • 需进一步研究ICI诱发类结节病反应的机制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immune checkpoint inhibitors (ICIs) are a newly developed component of cancer care that expands the treatment possibilities for patients. Their use has been associated with several immune-related adverse events, including ICI-induced sarcoidosis-like reactions. This article reviews the data concerning ICI-induced sarcoidosis-like reactions currently available in the medical literature. These reactions have been reported in three classes of ICIs: anti-cytotoxic T-lymphocyte associated protein 4 antibodies, programmed death 1 inhibitors and programmed death ligand 1 inhibitors. These reactions are indistinguishable from sarcoidosis with a similar histology, pattern of organ involvement, and pattern of clinical manifestations. The most common locations to observe granulomatous inflammation from these reactions is in intrathoracic locations (the lung and/or mediastinal lymph nodes) and the skin. The median time between initiation of an ICI and the development of a sarcoidosis-like reaction averaged 14 weeks. Clinicians have opted to use corticosteroids and/or discontinue the ICI, or take no action when these reactions have developed. Regardless of whether the clinician performed an intervention or not, these reactions have uniformly improved or resolved after ICI-treatment, which provides additional temporal evidence supporting the presence of a sarcoidosis-like reaction as opposed to sarcoidosis. There is even evidence that the development of an ICI-induced sarcoidosis-like reaction suggests that the ICI is effective as an anti-tumor agent and should be continued. As is the case for sarcoidosis, sarcoidosis-like reactions do not mandate antisarcoidosis therapy, especially if the condition is asymptomatic. When treatment of sarcoidosis-like reaction is required, it may be prudent to continue ICI therapy and add antisarcoidosis therapy because standard antisarcoidosis regimens seem to be effective. Further research into the mechanisms involved in the development of ICI-induced sarcoidosis-like reactions may give insights into the immunopathogenesis of sarcoidosis.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Gkiozos I, Kopitopoulou A, Kalkanis A, et al. Sarcoidosis-Like Reactions Induced by Checkpoint Inhibitors. J Thorac Oncol. 2018. PMID: 29763666. doi:10.1016/j.jtho.2018.04.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。